None
Quote | Arch Biopartners Inc (OTCMKTS:ACHFF)
Last: | $1.50 |
---|---|
Change Percent: | -0.97% |
Open: | $1.565 |
Close: | $1.50 |
High: | $1.57 |
Low: | $1.5 |
Volume: | 50,975 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Arch Biopartners Inc (OTCMKTS:ACHFF)
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II tria...
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pa...
Message Board Posts | Arch Biopartners Inc (OTCMKTS:ACHFF)
Subject | By | Source | When |
---|---|---|---|
$ACHFF ARch Biopartners Inc (QB) | mick | investorshub | 04/30/2023 9:23:37 PM |
$ACHFF ARch Biopartners Inc (QB) | mick | investorshub | 04/15/2023 3:40:59 PM |
$ACHFF ARch Biopartners Inc (QB) | mick | investorshub | 02/27/2023 1:03:03 AM |
$ACHFF ARch Biopartners Inc (QB) | mick | investorshub | 02/21/2023 11:01:09 PM |
$ACHFF ARch Biopartners Inc (QB) | mick | investorshub | 02/05/2023 11:11:11 PM |
News, Short Squeeze, Breakout and More Instantly...
Arch Biopartners Inc Company Name:
ACHFF Stock Symbol:
OTCMKTS Market:
Arch Biopartners Inc Website:
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II tria...
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pa...
TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevent...